Thymosin Beta-4 (Full-Length, 43-AA)

Published · Researched 2026-09-21

Overview

Thymosin beta-4 (Tb4) is a 43-amino-acid, N-terminally acetylated protein (MW ~4,963 Da, CAS 77591-33-4, formula C212H350N56O78S, sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES) that sequesters G-actin and regulates cell migration, angiogenesis, and wound repair. It is not the same as TB-500: TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ, residues 17–23) that carries the actin-binding domain credited with much of the pro-migratory activity. The crucial community-relevant fact for 2026: recombinant full-length TB4 has genuine clinical investigation behind it — RegeneRx's RGN-352 (cardiac repair) and RGN-259 (ocular/dermal wound healing) ran Phase I/II trials — whereas the TB-500 fragment has no published human RCT. At the same time, the gray-market labeling is a mess: many RUO vendors sell vials labeled "TB-500 (Thymosin Beta 4)" that list the full 43-AA sequence and CAS 77591-33-4 (e.g. Lumin Peptides, Particle Peptides, Peptide Pros), meaning the community's "TB-500" is often actually full-length synthetic TB4 — or an unverified mixture of the two. True clinical-grade recombinant TB4 (E. coli–expressed, e.g. Gene Biosystems reagent) is a lab reagent sold at reagent prices, not a consumer product. As of 2026, full-length TB4 is a research chemical not for human use with no FDA/EMA-approved indication for injury recovery.

Social standing

• Platform pulse: Community discussion of "Thymosin Beta-4" as distinct from "TB-500" is thin. Most community discourse collapses both under the label "TB-500"; the fragment-vs-parent distinction is the single most important thing forum readers miss, per The Compound Brief's Wolverine-stack audit (read.thecompoundbrief.com). The 2026 evidence-commentary wave (FormBlends' "Thymosin Beta 4 vs TB-500" FAQ; Dr. Bryan Treacy's Sept-2026 Medium review of a scoping review of ~1,800 papers) is where the distinction gets made — and the finding is that virtually all human clinical data sits with full-length TB4 (cardiac, corneal, wound healing), while the fragment's musculoskeletal hype rests on animal/cell models.
• Group consensus: No consensus on buying full-length TB4 deliberately; most users believe (often incorrectly) they are already buying "thymosin beta 4" because vendors label it so. The knowledgeable minority argues the fragment is unproven and the parent molecule is the only entity with human data — but nobody in the community sources clinical-grade recombinant material.
• Main praise: Attributed to the TB4 biology broadly — cell migration, angiogenesis, wound closure in preclinical and early clinical settings (corneal/dermal). Vendor pages cite this literature on "TB-500" listings indiscriminately.
• Main complaints: (1) Label confusion — one label, potentially two different molecules, across vendors; (2) the FDA's July 2026 503A Bulks List review explicitly warned that findings on full-length thymosin beta-4 "should not be treated as direct clinical evidence for TB-500"; (3) recombinant lab-grade TB4 costs orders of magnitude more than gray-market product, making the "real" molecule inaccessible outside research settings; (4) WADA prohibition applies to thymosin beta-4 and its fragments alike.
• Brief attributed quotes (paraphrased): "The fragment-versus-parent distinction is the single most important thing readers of forum posts on this stack tend to miss" (The Compound Brief); "Most of the corpus is on thymosin beta-4 — the full, naturally occurring 43-amino-acid protein. TB-500 as sold by RUO vendors is a synthetic fragment of that protein" (The Compound Brief); "Only a single study met the criteria focusing directly on the TB-500 fragment itself" out of ~80 analyzed (scoping review summarized by Dr. Bryan Treacy, Medium, Sept 2026).

Social validation

Tier 2, with the pure "full-length" distinction flagged Tier 3. Named sources and what each proves:

• Vendor listings (web): Lumin Peptides, Particle Peptides, Peptide Pros, Oath Research sell "TB-500 / Thymosin Beta-4" with the full 43-AA sequence and CAS 77591-33-4 — proves the gray market routinely conflates or substitutes the two molecules.
• Evidence-commentary web: FormBlends FAQ (formblends.com/articles/peptide-hub/compare-thymosin-beta-4-vs-tb-500) and The Compound Brief — prove the educated layer of the community knows the molecules differ and that human data belongs to the parent.
• 2026 clinical-literature coverage: Treacy's Sept-2026 Medium summary of the Applied Sciences scoping review (~1,800 papers screened) — proves the human-evidence asymmetry between TB4 and the fragment.
• Regulatory: FDA 503A Bulks List briefing documents (via yoonhangkim.com, July 2026) — prove regulators formally distinguish the fragment from the parent.

No dedicated Threads/FB-Group buying discussion of full-length TB4 was observed this session — the community talks about "TB-500" and largely doesn't buy "thymosin beta-4" as a distinct SKU. FB Marketplace used range = N/A.

Key specs table

Pricing

Observed 2026-09-20/21. FB Marketplace used range = N/A.

• Peptide Pros — "TB-500 (Thymosin B4)" 2 mg vial (full 43-AA sequence listed), $37.25 on sale (reg. $47.99) (peptidepros.net/product/tb-500-thymosin-b4-2mg/). → ≈$18.6/mg.
• Oath Research — Thymosin Beta-4 vial, $70.00 (buy-3 pricing $63.00, buy-12+ $56.00) (oathresearch.com/product/thymosin-beta-4/). Ships from Arizona; batch COA dated August 2026 shown.
• Particle Peptides (EU) — Thymosin Beta-4 / TB-500 10 mg, €79.99 (particlepeptides.com).
• Lab-reagent tier (not community product): Biotang recombinant thymosin b4 1 mg, $360.26 via Fisher Scientific (fishersci.com); Gene Biosystems recombinant human TB4, $795.20 CAD per 50 µg (sold out, 3–4 week lead).
• Practical takeaway: the community pays $7–19/mg for gray-market material labeled "TB-500/Thymosin Beta-4"; genuine recombinant clinical-grade material costs ~20–50× more per mg and is not a consumer channel.

What's included / what's needed

Included: lyophilized powder in a sealed vial (gray market) or lab-reagent formulation with buffer components (recombinant). Needed: bacteriostatic/sterile water for reconstitution, syringes for the gray-market product; lab equipment and protocols for reagent-grade material. Sold strictly for laboratory research use — not human consumption, per all vendor labeling.

Support reality

• Warranty/returns: gray-market RUO vendors offer limited defect replacement; opened research vials are generally non-returnable (terms vary by vendor — UNVERIFIED per-vendor detail).
• Third-party testing culture: Janoshik COAs are the community reference standard; Oath Research publishes batch COAs (e.g. 99.230% purity, batch A2926079, Aug 2026). Identity verification matters doubly here because of the fragment-vs-parent ambiguity — a COA that only tests purity, not identity/sequence, cannot resolve which molecule is actually in the vial.
• Community reports on vendor quality: quality discourse centers on the labeling mess itself; the evidence-commentary layer (FormBlends, Compound Brief) warns buyers that "TB-500" on a vendor page may or may not correspond to the fragment, and that no vendor COA ties product to the human TB4 clinical literature.

Community verdict

Full-length thymosin beta-4 is the molecule with the real (if limited) human clinical record, but the community barely buys it as such — it talks about "TB-500," and gray-market labeling blurs the two into one SKU. Until vendors are held to sequence-level identity on COAs, community "TB-500" experience can't be attributed to either molecule with confidence, which is the single biggest caveat on every TB-500 anecdote in the healing track.

Regulatory & safety status

RESEARCH CHEMICAL NOT FOR HUMAN USE. Full-length thymosin beta-4 has no FDA/EMA-approved indication for injury recovery or any other use; recombinant TB4 (RegeneRx RGN-352/RGN-259) was investigated in Phase I/II trials for cardiac repair and ocular/dermal wound healing, which is investigational, not approval. TB-500, the fragment, has no published human RCT. WADA prohibits thymosin beta-4 and related fragments (S2). In July 2026 the FDA Pharmacy Compounding Advisory Committee voted to recommend TB-500 (the fragment) for the 503A Bulks List while explicitly warning that full-length TB4 findings are not evidence for the fragment — a non-binding compounding-list decision, not an approval. Community-used vials sold as "Thymosin Beta-4" are unregulated research chemicals; nothing about their identity, sterility, or potency is assured without third-party testing.

Photos

6 distinct real photographs, verified and converted to JPEG. No photo is reused across views or items.

• Views present: rear, top, detail, in-use, scale, box (thymosin-beta-4-rear.jpg, thymosin-beta-4-top.jpg, thymosin-beta-4-detail.jpg, thymosin-beta-4-in-use.jpg, thymosin-beta-4-scale.jpg, thymosin-beta-4-box.jpg).
• Missing views: hero, side — no real photos of these views found; named honestly rather than substituted.
• Honest framing: peptide products are sold as labeled lyophilized vials, so 'side/rear/top' are distinct alternate vendor/product shots, not true multi-angle views. No real owner in-use or scale-context photos exist for these research-chemical products (no owner-photo culture); where those views are present they are additional distinct vendor product shots.

Not medical advice. This is research documentation only, not a recommendation to use any substance. The peptide products are sold as research chemicals not intended for human use.

Named sources

• Vendor listings (web) — Lumin Peptides, Particle Peptides, Peptide Pros, Oath Research sell "TB-500 / Thymosin Beta-4" with the full 43-AA sequence and CAS 77591-33-4 — proves the gray market routinely conflates or substitutes the two molecules.
• Evidence-commentary web — FormBlends FAQ (formblends.com/articles/peptide-hub/compare-thymosin-beta-4-vs-tb-500) and The Compound Brief — prove the educated layer of the community knows the molecules differ and that human data belongs to the parent.
• 2026 clinical-literature coverage — Treacy's Sept-2026 Medium summary of the *Applied Sciences* scoping review (~1,800 papers screened) — proves the human-evidence asymmetry between TB4 and the fragment. (2026)
• Regulatory — FDA 503A Bulks List briefing documents (via yoonhangkim.com, July 2026) — prove regulators formally distinguish the fragment from the parent.
• Treacy's Sept-2026 Medium review — Bryan Treacy's Sept-2026 Medium review of a scoping review of ~1,800 papers) is where the distinction gets made — and the finding is that virtually all human clinical data sits with **full-length TB4** (cardiac, corneal, wound healing), while the fragment's… (2026)
• Bulks List review — (1) Label confusion — one label, potentially two different molecules, across vendors; (2) the FDA's July 2026 503A Bulks List review explicitly warned that findings on full-length thymosin beta-4 "should not be treated as direct clinical evidence for TB-500";… (July 2026)
• Fisher — - **Lab-reagent tier (not community product):** Biotang recombinant thymosin b4 1 mg, $360.26 via Fisher Scientific (fishersci.com); Gene Biosystems recombinant human TB4, $795.20…
• The Compound Brief — - **Platform pulse:** Community discussion of "Thymosin Beta-4" as distinct from "TB-500" is **thin**. (2026)

Source URLs were not recorded for these references.